We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Hemorrhagic Fever Viruses Could Be Bioweapons

By Biotechdaily staff writers
Posted on 27 May 2002
Hemorrhagic fever viruses such as Ebola, Marburg, and Lassa could be used as biologic weapons, according to a report from a panel of experts convened by the Center for Civilian Biodefense Strategies at the Johns Hopkins Bloomberg School of Public Health (Baltimore, MD, USA). More...
The panel's consensus statement was published in the May 8, 2002, issue of the Journal of the American Medical Association (JAMA).

Hemorrhagic fever viruses are considered "Category A” biologic weapons agents by the US Centers for Disease Control and Prevention (CDC) because they have the potential to cause widespread illness and death. The panel's report focused on eight viruses: Ebola, Marburg, Lassa fever, New World Arenavirus, Rift Valley fever, yellow fever, Ornsk hemorrhagic fever, and Kyasanur Forest disease. Ebola and Marburg are among the most deadly of these. Ebola kills 50-90% of those infected, and Marburg is fatal in 23-70% of cases.

There are no widely available diagnostic tests for these viruses, and few effective therapies or vaccines are available to treat them. The panel says strict infection controls need to be used during an outbreak, since many of the viruses can be spread by person-to-person contact. Patients should be isolated, and clinicians should wear protective gear.

"The Working Group's consensus recommends improvement to our diagnostic capacity and the development of a rapid test for diagnosing hemorrhagic fever viruses,” said Luciana Borio, M.D., lead author and a fellow at the Hopkins Center for Civilian Biodefense Strategies. "Research efforts should also focus on new antiviral medications, vaccines, and a more fundamental scientific study of the viruses that cause hemorrhagic illness.”




Related Links:
Center for Civilian Biodefense
JAMA

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
POC Immunoassay Analyzer
Procise DX
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Dr. Olivia Belbin, head of the Molecular Neurodegeneration Group at IR Sant Pau and study corresponding author, with Alba Cervantes (right), first author and IR Sant Pau researcher (Photo courtesy of IR Sant Pau)

Blood Biomarker Detects Alzheimer’s Changes Decades Before Symptoms in Down Syndrome

Alzheimer’s disease can begin altering the brain long before clinical symptoms appear, creating a challenge for early-stage detection and research. People with Down syndrome face a particularly high age-related... Read more

Molecular Diagnostics

view channel
Photo courtesy of National Human Genome Research Institute

Genomic Screening Expands Detection of Treatable Conditions in Newborns

Conventional newborn screening can miss conditions that lack biochemical biomarkers or present atypically. Initial hearing screens may also fail to detect hearing loss that is later identified through... Read more

Microbiology

view channel
Image: Invasive aspergillosis (IA) is a potentially life-threatening infection caused by Aspergillus mold that primarily affects people with severely weakened immune systems. (Image Credit: Adobe Stock)

Rapid Urine Test Aids Diagnosis of Invasive Aspergillosis

Invasive aspergillosis is an uncommon mold infection in the general population but can pose serious risks for people with weakened immune defenses. Diagnosis can be difficult because existing approaches... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: NMPA approvals for Quanterix HD-X and SR-X instruments and four neurology biomarker assays expand access to ultrasensitive blood-based testing in China (Photo courtesy of Quanterix Corporation)

Regulatory Milestone Expands Access to Blood-Based Neurology Biomarker Testing in China

Quanterix Corporation (Billerica, MA, USA) and Innovita Biological Technology Co., Ltd. (Beijing, China) announced regulatory approvals that expand access to Quanterix SIMOA technology and neurology biomarker... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.